Log in to search using one of your social media accounts:

 

COPD (Chronic Obstructive Pulmonary Disease) Symptoms, Causes, Stages, Life Extpectancy

Title: COPD (Chronic Obstructive Pulmonary Disease) Symptoms, Causes, Stages, Life ExtpectancyCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 2/6/2018 12:00:00 AM
Source: MedicineNet Lungs General - Category: Respiratory Medicine Source Type: news

Related Links:

Publication date: 15 September 2018 Source:Journal of Molecular Structure, Volume 1168 Author(s): Lei-Lei Huang, Jie Han, Jian-Xiong Ran, Xiu-Ping Chen, Zhong-Hua Wang, Fan-Hong Wu Dipeptidyl peptidase I (DPPI) inhibitors have potential use in the treatment of neutrophil inflammatory diseases, such as chronic obstructive pulmonary disease. The three-dimensional quantitative structure-activity relationship (3D-QSAR) model was established in this paper based on the computational biology method for 32 DPPI inhibitor compounds. Good predictability was obtained based on the application of the comparative molecular field analys...
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
An overview of glycopyrrolate/eFlow® CS in COPD. Expert Rev Respir Med. 2018 May 18;: Authors: Kerwin E, Ferguson GT Abstract INTRODUCTION: COPD is highly prevalent in the US and globally, requiring new treatment strategies due to the high disease burden and increase in the aging population. Here, we profile the newly FDA-approved LONHALA MAGNAIR (glycopyrrolate [GLY]/eFlow® Closed System [CS]; 25 mcg twice daily), a nebulized long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of COPD, including chronic bronchitis and/or emphysema. Areas covered: An overview of COP...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
We read with interest the letter to the editor by Prof. Kawada, and appreciate the points that were raised. First, we agree that we did not adjust for severity of chronic obstructive pulmonary disease (COPD) in our analysis of administrative claims data.1 Inability to adjust for severity of disease is a known limitation of such administrative claims analysis.2 However, it is for that reason that we adjusted for concomitant medications and propensity scores — which, although it is not the same as severity assessment using spirometry or imaging — offers a means to account for severity of COPD.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Letter Source Type: research
I read the article by Vasquez et  al1 with interest. The prevalences of noninvasive positive pressure ventilation, bilevel positive airway pressure, and continuous positive airway pressure in patients with chronic obstructive pulmonary disease were
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Letter Source Type: research
Low physical activity (PA) is associated with adverse health outcomes independent of airflow limitation in COPD. Self-reported assessments are often limited to global estimates of PA and may not be directly translatable to patients' goals and motivations. We developed a task-oriented PA checklist and examined its performance relative to pedometer-assessed daily step count in two COPD cohorts.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Source Type: research
Conclusions: Procaterol assist use modestly but significantly improved pulmonary function determined by spirometry and respiratory mechanics in patients with stable COPD treated with long-acting bronchodilators. Thus, inhaled procaterol has potential for assist use for COPD.
Source: Medical Principles and Practice - Category: Internal Medicine Source Type: research
Conclusion Theophylline clearance was significantly associated with FFM and CYP1A2*1B genotypes in Chinese adult patients.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
IJERPH, Vol. 15, Pages 1021: Analysis of Short-Term Smoking Effects in PBMC of Healthy Subjects—Preliminary Study International Journal of Environmental Research and Public Health doi: 10.3390/ijerph15051021 Authors: Joanna Wieczfinska Tomasz Kowalczyk Przemyslaw Sitarek Ewa Skała Rafal Pawliczak Early structural changes exist in the small airways before the establishment of Chronic Obstructive Pulmonary Disease (COPD). These changes are believed to be induced by oxidation. The aim of this study was to analyze the influence of short-term smoking on the expression of the genes contributing to airway r...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
We examined questions using the National Health and Nutrition Examination Survey III database linked to the National Death Index. The data from 4434 participants were stratified into 4 groups, those with asthma, COPD, ACO, and those without any obstructive lung disease. We examined baseline demographics and used multivariate logistic regression to model the impact of demographics, smoking, and self-reported, physician-diagnosed lung disease on mortality generating odds ratios (ORs) and confidence intervals (CIs). RESULTS: Among 4434 participants, 120 (2.7%), 340 (7.6%), and 126 (2.8%) participants self-reported diagnos...
Source: Southern Medical Journal - Category: General Medicine Tags: South Med J Source Type: research
Acta Ophthalmologica, EarlyView.
Source: Acta Ophthalmologica - Category: Opthalmology Authors: Source Type: research
More News: Chronic Obstructive Pulmonary | Respiratory Medicine